MAZE
HEALTHCAREMaze Therapeutics Inc
$26.47-0.09 (-0.34%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MAZE Today?
No stock-specific AI insight has been generated for MAZE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.24$53.65
$26.47
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-3.05
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume325K
Avg Volume (10D)—
Shares Outstanding55.2M
MAZE News
20 articles- Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 FinancialsMotley Fool·May 7, 2026
- What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to BuyYahoo Finance·Apr 26, 2026
- Maze Therapeutics Announces $150 Million Registered OfferingGlobeNewswire Inc.·Apr 22, 2026
- Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant ImpactYahoo Finance·Apr 21, 2026
- Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated StocksYahoo Finance·Apr 8, 2026
- Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.The Motley Fool·Apr 4, 2026
- After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)Yahoo Finance·Mar 27, 2026
- Why Maze Therapeutics Plunged 35% Despite 'Overwhelming Positive' DataYahoo Finance·Mar 25, 2026
- Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney DiseaseMarketbeat·Mar 25, 2026
- Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%Motley Fool·Mar 25, 2026
- Maze set to target Vertex as kidney disease drug succeeds in Phase II trialClinicaltrialsarena·Mar 25, 2026
- Top Midday DeclinersYahoo Finance·Mar 25, 2026
- Maze tumbles despite positive data for kidney disease drugBiopharmadive·Mar 25, 2026
- Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney DiseaseYahoo Finance·Mar 25, 2026
- Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent HighlightsYahoo Finance·Mar 25, 2026
- Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report NearsMotley Fool·Mar 22, 2026
- Block upgraded, Starbucks downgraded: Wall Street's top analyst callsYahoo Finance·Mar 18, 2026
- Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price MomentumYahoo Finance·Mar 13, 2026
- Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC FilingMotley Fool·Feb 18, 2026
All 20 articles loaded
Price Data
Open$26.69
Previous Close$26.56
Day High$27.26
Day Low$26.27
52 Week High$53.65
52 Week Low$8.24
52-Week Range
$8.24$53.65
$26.47
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-3.05
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume325K
Avg Volume (10D)—
Shares Outstanding55.2M
About Maze Therapeutics Inc
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—